138
Participants
Start Date
April 26, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
TRK-950
10 mg/kg administered intravenously over 60 minutes (weekly)
TRK-950
5 mg/kg administered intravenously over 60 minutes (weekly)
TRK-950
Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)
Irinotecan
Intravenously over 30 - 90 minutes
Leucovorin
Intravenously over 30 - 90 minutes
5-FU
Intravenously bolus and intravenously for two days
Gemcitabine
Intravenously over 30 minutes
Cisplatin
Intravenously over 60 minutes
Carboplatin
Intravenously per package insert
Ramucirumab
Intravenously over 60 minutes
Paclitaxel
Intravenously
Nivolumab
Intravenously over 30 minutes
Pembrolizumab
Intravenously over 30 minutes
Imiquimod Cream
Topically
Bevacizumab
Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses
PLD
Intravenously over 60 minutes
Perlmutter Cancer Center at NYU Langone, New York
Virginia Cancer Specialists, PC, Leesburg
Medical College of Wisconsin, Milwaukee
Centre Léon Bérard, Lyon
Ochsner Clinic Foundation, New Orleans
Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology - Downtown Fort Worth Cancer Center, Fort Worth
HonorHealth Research Institute, Scottsdale
AOA-HOPE, Tucson
USC Norris Comprehensive Cancer Center, Los Angeles
HOAG Memorial Hospital Presbyterian, Newport
Northwest Cancer Specialists, Portland
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center), Eugene
Atlantic Health System, Morristown
Toray Industries, Inc
INDUSTRY